Jump to content

Apitegromab

Edit links
From Wikipedia, the free encyclopedia

Apitegromab
Monoclonal antibody
TypeWhole antibody
SourceHuman
TargetPromyostatin
Clinical data
Trade namesIsembyld
Other namesSRK-015, apitegromab-mstn
AHFS/Drugs.comIsembyld
License data
Routes of
administration		Intravenous
ATC code
Legal status
Legal status
Identifiers
CAS Number
UNII
KEGG
Chemical and physical data
FormulaC6412H9866N1710O2026S44
Molar mass144736.04 g·mol−1

Apitegromab, sold under the brand name Isembyld, is a fully human IgG4 lambda monoclonal antibody used for the treatment of spinal muscular atrophy.[1] It is a recombinant monoclonal antibody targeting proforms of myostatin.[1]

The most common side effects include upper respiratory tract infections, vomiting, cough, other viral infections, headache, gastroenteritis, and pharyngitis (sore throat).[2]

Apitegromab was approved for medical use in the United States in September 2026.[2]

Medical uses

[edit]

Apitegromab is indicated for the treatment of spinal muscular atrophy in people aged two years of age and older who are currently receiving a survival motor neuron 2-targeted treatment.[1] Spinal muscular atrophy is a rare, progressive neuromuscular disease affecting approximately 1 in 10,000 live births and is among the leading genetic causes of infant mortality.[2] It is caused by a faulty survival motor neuron 1 (SMN1) gene that fails to produce a protein essential for motor neuron survival, leading to progressive muscle weakness and wasting.[2]

Adverse effects

[edit]

The most common adverse reactions include upper respiratory tract infections, vomiting, cough, other viral infections, headache, gastroenteritis, and pharyngitis (sore throat).[2] An increased risk of fractures, including serious fractures, was observed in people treated with apitegromab.[2] Apitegromab may cause fetal harm and may affect reproductive function.[2]

History

[edit]

The effectiveness and safety of apitegromab were evaluated in a 52-week randomized, double-blind, placebo-controlled trial (NCT05156320).[2] The trial enrolled 188 participants with spinal muscular atrophy between 2 to 21 years of age who were not able to move or walk independently.[2] All participants were already receiving an approved survival motor neuron 2-targeted treatment.[2] Participants were randomly assigned to receive apitegromab 10 mg/kg, apitegromab 20 mg/kg via intravenous infusion, or placebo once every four weeks for approximately one year.[2] The primary analysis was conducted in 156 participants aged 2 to 12 years of age.[2]

Society and culture

[edit]
[edit]

In August 2026, Scholar Rock Netherlands withdrew its application for a marketing authorization of Isembyld for the treatment of 5q spinal muscular atrophy.[3] The company stated that the manufacturing site used to make the medicine had not demonstrated compliance with EU GMP requirements within the required time limit.[3]

Apitegromab was authorized for medical use in the United States in September 2026.[4][5]

The US Food and Drug Administration (FDA) granted the application for apitegromab fast track, orphan drug, and rare pediatric disease designations.[2] The FDA granted the approval of Isembyld to Scholar Rock.[2]

Research

[edit]

Apitegromab is under investigation for Facioscapulohumeral Muscular Dystrophy (FSHD)[6] and to reduce lean mass loss during treatment with GLP-1 receptor agonists.[7]

Names

[edit]

Apitegromab is the international nonproprietary name.[8]

Apitegromab is sold under the brand name Isembyld.[4]

References

[edit]
  1. 1 2 3 4 "Isembyld- apitegromab-mstn injection". DailyMed. 14 September 2026. Retrieved 13 October 2026.
  2. 1 2 3 4 5 6 7 8 9 10 11 12 13 14 "FDA Approves First Therapy to Target Muscle Loss in Spinal Muscular Atrophy". U.S. Food and Drug Administration (FDA). 11 September 2026. Retrieved 15 September 2026. Public Domain This article incorporates text from this source, which is in the public domain.
  3. 1 2 "Isembyld EPAR". European Medicines Agency (EMA). 21 August 2026. Retrieved 15 September 2026. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
  4. 1 2 "Scholar Rock Announces FDA Approval of Isembyld (apitegromab-mstn), the First and Only Muscle-Targeted Treatment for Children and Adults with Spinal Muscular Atrophy (SMA)" (Press release). Scholar Rock. 11 September 2026. Retrieved 15 September 2026 – via business Wire.
  5. ↑ "FDA Approves Isembyld for People Living with SMA" (Press release). Cure SMA. 14 September 2026. Retrieved 15 September 2026 – via PR Newswire.
  6. ↑ "Scholar Rock Receives FDA Fast Track Designation for Apitegromab Facioscapulohumeral Muscular Dystrophy (FSHD) Program as Participant Dosing Commences in Phase 2 FORGE Trial". Biospace. 2 September 2026. Retrieved 10 October 2026.
  7. ↑ "Scholar Rock Reports Positive Phase 2 EMBRAZE Trial Results Demonstrating Statistically Significant Preservation of Lean Mass with Apitegromab During Tirzepatide-Induced Weight Loss". Biospace. 18 June 2025. Retrieved 10 October 2026.
  8. ↑ World Health Organization (2021). "International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 85". WHO Drug Information. 35 (1). hdl:10665/340684.

Further reading

[edit]
[edit]
Retrieved from "https://en.wikipedia.org/w/index.php?title=Apitegromab&oldid=1379997391"